Related Experiment Videos
Adiponectin, obesity, and cardiovascular disease
Mathias Fasshauer1, Ralf Paschke, Michael Stumvoll
1Department of Internal Medicine III, University of Leipzig, Rosenthal-Street 27, 04103 Leipzig, Germany.
Biochimie
|December 14, 2004
Summary
Adiponectin, an adipokine, is decreased in obesity and linked to insulin resistance and cardiovascular disease. This review summarizes adiponectin
Area of Science:
- Endocrinology
- Metabolic Syndrome
- Cardiovascular Research
Background:
- Obesity is linked to insulin resistance and cardiovascular disease through adipocyte-secreted factors.
- Adiponectin is an insulin-sensitizing and anti-inflammatory adipokine with reduced levels in obesity-associated disorders.
- Adiponectin receptors (AdipoR) mediate effects via adenosine monophosphate kinase (AMPK) and acetyl coenzyme A carboxylase (ACC).
Purpose of the Study:
- To review the regulation and function of adiponectin.
- To discuss the role of adiponectin in obesity, insulin resistance, and cardiovascular disease.
- To explore the clinical implications of adiponectin modulation.
Main Methods:
- Literature review of current knowledge on adiponectin.
- Analysis of adiponectin's role in metabolic and vascular pathophysiology.
- Discussion of clinical relevance, including drug effects (e.g., TZDs).
Main Results:
- Adiponectin exhibits insulin-sensitizing, anti-inflammatory, and vasoprotective effects.
- Reduced adiponectin levels are associated with obesity, insulin resistance, and cardiovascular disease.
- Thiazolidinediones (TZDs) increase adiponectin, while obesity-related hormones decrease it.
Conclusions:
- Adiponectin plays a crucial role in metabolic and cardiovascular health.
- Dysregulation of adiponectin contributes to obesity-associated pathologies.
- Understanding adiponectin's mechanisms offers therapeutic potential for type 2 diabetes and cardiovascular disease.